Login
Login
Register
Complete Your Profile
Change Password
Request a Password Reset
Download Documents
NATIONAL INSTITUTES OF HEALTH has floated a tender for Investigational New Drug (Ind)-Enabling and Early-Stage Development of Medications to Treat Alcohol Use Disorder and Alcohol-Associated Organ Damage (Ut1/Ut2 Clinical Trial Optional). The project location is USA and the tender is closing on 04 Dec 2024. The tender notice number is PAR-22-103, while the TOT Ref Number is 62384437. Bidders can have further information about the Tender and can request the complete Tender document by Registering on the site.
Procurement Summary
Country : USA
Summary : Investigational New Drug (Ind)-Enabling and Early-Stage Development of Medications to Treat Alcohol Use Disorder and Alcohol-Associated Organ Damage (Ut1/Ut2 Clinical Trial Optional)
Deadline : 04 Dec 2024
Other Information
Notice Type : Tender
TOT Ref.No.: 62384437
Document Ref. No. : PAR-22-103
Competition : ICB
Financier : Self Financed
Purchaser Ownership : -
Tender Value : Refer Document
Purchaser's Detail
Name :Login to see tender_details
Address : Login to see tender_details
Email : Login to see tender_details
Login to see detailsTender Details
Tender are invited for Investigational New Drug (IND)-enabling and Early-Stage Development of Medications to Treat Alcohol Use disorder and Alcohol-Associated Organ Damage (UT1/UT2 Clinical Trial Optional)
CFDA Number : 93.273 -- Alcohol Research Programs
Cost Sharing or Matching Requirement : No
Closing Date for Applications: Dec 04, 2024
Posted Date : Jan 21, 2022
Description: This Funding Opportunity Announcement (FOA) supports Small Business Technology Transfer (STTR) applications from small business concerns (SBCs) that propose the development of therapeutic agents for the treatment of alcohol use disorder (AUD) and/or alcohol associated organ damage (AAOD). As a starting point, eligible applicants must identify a therapeutic candidate with a robust body of background data in the basic science and early discovery phases to be ready for transition to the preclinical and clinical phases of development. Data may include having sufficient bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and/or target engagement, and other favorable properties that are consistent with the desired clinical application. Projects responsive to this announcement could be undertaken at any point along the drug development continuum, from late discovery (i.e., lead optimization/early safety) up to early-stage clinical trials. For small molecules, the earliest stage of eligibility for this Award is already having smal...
Documents
Want To Bid in This Tender?
Get Local Agent Support in USA and 60 More Countries.
View Tenders By
Sign in with Google